Novo Nordisk A/S, a leading global healthcare company, has reported on the progress of its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on August 7, 2024, targeting the repurchase of B shares for an amount up to DKK 2.4 billion by November 4, 2024. Since the last announcement on August 12, 2024, Novo Nordisk has acquired 335,187 B shares at an average price of DKK 879.32, amounting to a total transaction value of DKK 298,612,988. These transactions are separate from the company's incentive programs, which resulted in a net transfer of 14,129 B shares from August 12 to August 16, 2024. Novo Nordisk now holds 12,730,944 B shares as treasury shares, representing 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.

Novo Nordisk A/S, a leading global healthcare company, has reported on the progress of its share repurchase program. The program, which began on February 6, 2024, aims to buy back shares worth up to DKK 20 billion over a 12-month period. As part of this initiative, a specific share repurchase plan was initiated on August 7, 2024, targeting the repurchase of B shares for an amount up to DKK 2.4 billion by November 4, 2024. Since the last announcement on August 12, 2024, Novo Nordisk has acquired 335,187 B shares at an average price of DKK 879.32, amounting to a total transaction value of DKK 298,612,988. These transactions are separate from the company's incentive programs, which resulted in a net transfer of 14,129 B shares from August 12 to August 16, 2024. Novo Nordisk now holds 12,730,944 B shares as treasury shares, representing 0.3% of the share capital. The company's shares are traded on Nasdaq Copenhagen and its ADRs on the New York Stock Exchange.